The company had total revenues of $193.5 million during the quarter, driven by continued increases in revenue and test volume for its more recently launched and acquired tests.
HTG Molecular will provide Firalis with technology and components to support its commercialization of a rheumatoid arthritis theranostic assay.
The effort, which relied on Oxford BioDynamics' EpiSwitch platform, resulted in an assay that researchers believe could be developed into a test to guide therapy selection for patients.
The partners are initially planning to make searchable whole-genome data and EMRs from more than 1,000 rheumatoid arthritis patients accessible to trial developers.
The company said that it can distinguish patients suffering from lupus from those with other autoimmune diseases using its antibody array platform.
The deal joins Metabolon's metabolomics expertise with InnVentis' big data and machine learning platform.
Contractor Palmetto GBA issued a draft local coverage determination proposing ending coverage of the test based on factors including a recent critical study.
The researchers found that patients with periodontitis exhibited patterns of autoantigen hypercitrullination similar to those found in RA patients.
The studies looked at applications including predicting disease progression, guiding drug tapering, and identifying patients at risk of related conditions.
Results from the Rheumatoid Arthritis Responder Dream Challenge did not support the use of common SNP data to improve treatment response prediction models.
The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.
A small study finds differences between three genomic prostate cancer tests, Medscape reports.
In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.
A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.